Form 8-K - Current report:
SEC Accession No. 0000899923-25-000002
Filing Date
2025-01-15
Accepted
2025-01-15 08:39:14
Documents
15
Period of Report
2025-01-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-20250115.htm   iXBRL 8-K 35856
2 EX-99.1 mygnq4pre-announcementatjp.htm EX-99.1 112911
  Complete submission text file 0000899923-25-000002.txt   314552

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20250115.xsd EX-101.SCH 2021
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20250115_def.xml EX-101.DEF 14426
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20250115_lab.xml EX-101.LAB 25279
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20250115_pre.xml EX-101.PRE 15012
17 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20250115_htm.xml XML 2707
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 25531252
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)